Acura Pharmaceuticals
ACUR
ACUR was delisted on the 22nd of February, 2017.
30 hedge funds and large institutions have $22M invested in Acura Pharmaceuticals in 2013 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 13 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
5% less capital invested
Capital invested by funds: $23.1M → $22M (-$1.09M)
30% less funds holding
Funds holding: 43 → 30 (-13)
60% less call options, than puts
Call options by funds: $39K | Put options by funds: $98K
92% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$79.2K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$61K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$55.8K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$33.4K |
| 5 |
Goldman Sachs
New York
|
+$21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
-$284K |
| 2 |
Morgan Stanley
New York
|
-$202K |
| 3 |
OWD
Osborn Williams & Donohoe
Cincinnati,
Ohio
|
-$148K |
| 4 |
D.E. Shaw & Co
New York
|
-$143K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$105K |
ACUR Hedge Fund Activity: Q3 2013 in Review
30 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Acura Pharmaceuticals (ACUR) for Q3 2013, worth a combined $22M — down 4.7% from $23.1M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ACUR and 1 opened new positions — a net loss of 12 holders — while 10 trimmed existing stakes and 10 added.
The largest buyer was Geode Capital Management, adding an estimated $79.2K. The largest seller was Northern Trust, cutting an estimated $284K.
- 30 institutional investors held Acura Pharmaceuticals (ACUR) as of Q3 2013, down from 43 in Q2 2013.
- Funds reported $22M of Acura Pharmaceuticals stock for Q3 2013, down 4.7% quarter-over-quarter.
- 1 fund opened new Acura Pharmaceuticals positions in Q3 2013 and 13 closed out, a net change of -12 holders.
- The largest Acura Pharmaceuticals buyer in Q3 2013 was Geode Capital Management, an estimated $79.2K added.
- The largest Acura Pharmaceuticals seller in Q3 2013 was Northern Trust, an estimated $284K sold.
Based on aggregated 13F filings for Q3 2013.